-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shift From Loss To Profit
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shift From Loss To Profit
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company's loss has recently broadened since it announced a US$419m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$716m, moving it further away from breakeven. Many investors are wondering about the rate at which Sarepta Therapeutics will turn a profit, with the big question being "when will the company breakeven?" In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
Check out our latest analysis for Sarepta Therapeutics
Consensus from 16 of the American Biotechs analysts is that Sarepta Therapeutics is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$716m in 2024. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 55%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Given this is a high-level overview, we won't go into details of Sarepta Therapeutics' upcoming projects, though, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
One thing we would like to bring into light with Sarepta Therapeutics is its debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, which in this case, the company has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.
Next Steps:
This article is not intended to be a comprehensive analysis on Sarepta Therapeutics, so if you are interested in understanding the company at a deeper level, take a look at Sarepta Therapeutics' company page on Simply Wall St. We've also put together a list of key factors you should further research:
- Valuation: What is Sarepta Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Sarepta Therapeutics is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Sarepta Therapeutics's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company's loss has recently broadened since it announced a US$419m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$716m, moving it further away from breakeven. Many investors are wondering about the rate at which Sarepta Therapeutics will turn a profit, with the big question being "when will the company breakeven?" In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
赛瑞普塔治疗公司(纳斯达克代码:SRPT)可能会在业务上取得重大成就,所以我们想对该公司有所了解。Sarepta治疗公司是一家商业阶段的生物制药公司,专注于发现和开发RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的遗传疗法。自宣布整个财年亏损4.19亿美元以来,该公司的亏损最近有所扩大,而最新的往绩12个月亏损为7.16亿美元,进一步远离盈亏平衡。许多投资者想知道Sarepta Treateutics将以多快的速度盈利,最大的问题是“公司什么时候能实现盈亏平衡?”在这篇文章中,我们将触及对该公司增长的预期,以及分析师预计该公司何时能实现盈利。
Check out our latest analysis for Sarepta Therapeutics
查看我们对Sarepta Treeutics的最新分析
Consensus from 16 of the American Biotechs analysts is that Sarepta Therapeutics is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of US$716m in 2024. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 55%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
来自16家美国生物技术公司分析师的共识是,Sarepta治疗公司即将实现收支平衡。他们预计,该公司将在2023年公布最终亏损,然后在2024年实现7.16亿美元的盈利。因此,该公司预计将在一年多一点的时间内实现盈亏平衡。为了在这一天实现盈亏平衡,公司必须以多大的速度实现同比增长?使用一条最佳拟合线,我们计算出的年均增长率为55%,这表明分析师的信心很高。如果这一速度被证明过于激进,该公司实现盈利的时间可能比分析师预测的要晚得多。
Given this is a high-level overview, we won't go into details of Sarepta Therapeutics' upcoming projects, though, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
鉴于这只是一个高层次的概述,我们不会深入到Sarepta Treeutics即将到来的项目的细节,但要记住,总的来说,生物技术公司根据产品开发阶段的不同,有不定期的现金流。这意味着,即将到来的大幅增长并不是异常的,因为该公司正开始从早期的投资中获益。
One thing we would like to bring into light with Sarepta Therapeutics is its debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, which in this case, the company has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.
我们想要披露的一件事是Sarepta治疗公司的债务权益比超过2倍。一般来说,经验法则是债务不应超过股本的40%,在这种情况下,公司的债务已经大大超过了股本的40%。请注意,较高的债务义务会增加投资亏损公司的风险。
Next Steps:
接下来的步骤:
This article is not intended to be a comprehensive analysis on Sarepta Therapeutics, so if you are interested in understanding the company at a deeper level, take a look at Sarepta Therapeutics' company page on Simply Wall St. We've also put together a list of key factors you should further research:
本文无意对赛瑞普塔治疗公司进行全面分析,因此,如果你有兴趣更深入地了解该公司,不妨看看赛瑞普塔治疗公司在Simply Wall St.上的公司页面。我们还整理了一系列你应该进一步研究的关键因素:
- Valuation: What is Sarepta Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Sarepta Therapeutics is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Sarepta Therapeutics's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Sarepta Treeutics今天的价值是多少?未来的增长潜力已经计入价格因素了吗?我们免费研究报告中的内在价值信息图有助于直观地了解Sarepta治疗公司目前是否被市场错误定价。
- 管理团队:经验丰富的管理团队掌舵增加了我们对业务的信心--看看谁是Sarepta治疗公司董事会的成员和首席执行官的背景。
- 其他高表现股票:有没有其他股票可以提供更好的前景,并有经过证实的记录?在这里探索我们的这些伟大股票的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧